Evidence & regulatory context
- Mechanism
- Combination product; no confident single ChEMBL entity. Thymosin beta-4 is an actin-sequestering peptide and silver sulfadiazine a topical antibacterial.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Silvathymosin; Thymosin beta-4; Tbeta4; Silver sulfadiazine
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatWoundTopical
Model: Large full-thickness clean or infected skin wounds
In clean wounds silvathymosin gave the fastest healing at 85 per cent compared with 84 per cent for silver sulfadiazine and 72 per cent for thymosin beta-4 alone, while in infected wounds thymosin beta-4 and silvathymosin did not show comparable healing.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
